Peptides and GLP-1 Drugs: What You Need to Know

At a Glance

GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) are the most significant weight loss drugs in modern medicine. They work. The question for men over 40 isn’t whether they cause weight loss — it’s whether you’re losing the right kind of weight. Up to 40% of the weight lost on these drugs can be lean body mass, not fat. That’s a real problem if you’re already fighting age-related muscle loss.
The muscle loss problem is solvable but not automatic. Resistance training 2-3 times per week plus high protein intake (1.2-2g per kg of bodyweight daily) during GLP-1 therapy is what the evidence supports for preserving muscle. Without that, you’re accelerating sarcopenia — the exact thing men over 40 should be fighting.
Beyond GLP-1s, the broader peptide world (BPC-157, TB-500, GHK-Cu, Semax, Selank) is a different landscape entirely. Some have legitimate clinical data. Most are running far ahead of the evidence, with strong animal research but almost no human trials.
I’ve used several of these personally — retatrutide for weight loss, GHK-Cu for recovery (didn’t notice much), the GLOW stack (BPC-157 + TB-500 + GHK-Cu), and Semax and Selank for anxiety (which I found genuinely helpful). I’ll be honest about what worked, what didn’t, and what the research actually supports.
The sourcing and quality problem is real. Most peptides sold online are unregulated, manufactured without FDA oversight, and marketed as “research chemicals.” What’s in the vial may not match the label. This matters.

Part 1: GLP-1 Receptor Agonists — The Weight Loss Revolution (and Its Muscle Problem)

What These Drugs Actually Are

If you’ve heard of Ozempic, Wegovy, or Mounjaro, you’ve heard of GLP-1 receptor agonists. These drugs mimic hormones your gut naturally produces after eating — hormones that tell your brain you’re full, slow down stomach emptying, and regulate blood sugar. The result is dramatically reduced appetite and, in most people, significant weight loss.

There are three main players right now:

Semaglutide (brand names Ozempic for diabetes, Wegovy for weight loss) — This is the one that started the cultural conversation. Published clinical trials show average weight loss of about 15% of body weight over 68 weeks. It works on one receptor: GLP-1.
Tirzepatide (brand name Mounjaro for diabetes, Zepbound for weight loss) — A dual agonist that hits both GLP-1 and GIP receptors. Clinical trials show average weight loss of 20-22% of body weight — meaningfully more than semaglutide. Currently the most potent approved option.
Retatrutide — A triple agonist hitting GLP-1, GIP, and glucagon receptors. Still in clinical trials (Phase 3 results started coming in late 2025), but Phase 2 data published in the New England Journal of Medicine showed up to 24.2% weight loss at 48 weeks. Phase 3 showed an average of 71.2 lbs lost. If approved, this would be the most effective weight loss drug ever brought to market.

I have personal experience with retatrutide — I documented my full dosage schedule, weight data, and results in a separate article. What I’ll say here is that these drugs are not overhyped. They produce real, substantial weight loss in most people who take them.

But that’s only half the story.

The Muscle Loss Problem: Why This Matters More After 40

Here’s what most of the breathless media coverage of GLP-1 drugs doesn’t talk about: you’re not just losing fat.

Body composition analyses from clinical trials show that up to 40% of the total weight lost on high-efficacy GLP-1 medications is lean body mass — muscle, not fat. One analysis found semaglutide users losing 13.9% of their lean muscle mass during treatment. A 2026 preprint comparing tirzepatide to semaglutide in real-world use found that tirzepatide caused about 2% more lean body mass loss than semaglutide at 12 months — likely because it produces greater total weight loss.

For a 25-year-old with plenty of muscle reserve, losing some lean mass during a weight loss phase is annoying but manageable. For a man over 40 who’s already losing 3-5% of his muscle mass per decade to sarcopenia, it’s a completely different calculation. You’re stacking drug-induced muscle loss on top of age-related muscle loss, and the result can be a skinnier version of yourself that’s actually weaker and more fragile than before.

This is why geriatric specialists and researchers are now raising alarms about GLP-1 prescriptions in adults over 65 — where the risk of sarcopenia, frailty, and reduced functional independence is highest. A 2026 report flagged that Medicare coverage expansions are putting millions of older Americans on these drugs without adequate baseline assessment, slower dosing protocols, or proactive muscle monitoring.

How to Use GLP-1 Drugs Without Losing Your Muscle

The muscle loss problem is solvable. But it requires deliberate effort — it won’t happen by default.

Resistance training is non-negotiable. If you’re on a GLP-1 drug and you’re not strength training 2-3 times per week, you’re almost certainly losing more muscle than you need to. The research comparing tirzepatide to semaglutide found that reduced exercise tolerance was associated with greater lean mass decline in both groups, but the effect was more pronounced in tirzepatide patients. Exercise isn’t optional when you’re on these drugs — it’s part of the treatment.

If you’re not currently training, see my Beginner’s Guide to Weightlifting or the Strength Training After 60 guide if you’re in that age range. If you need a home setup to make it consistent, I wrote a full breakdown of home gym equipment for men over 40.

Protein intake needs to be high. The evidence-based target during GLP-1 therapy is 1.2 to 2g of protein per kg of body weight daily. That’s aggressive, and it’s harder to hit when your appetite is suppressed — which is exactly what these drugs do. Protein shakes, high-protein snacks, and front-loading protein at every meal become practical necessities, not just nice-to-haves.

For a detailed breakdown of protein needs and supplementation, see my articles on supplements for muscle loss after 50 and creatine.

Creatine may help. There’s no direct study on creatine plus GLP-1 therapy specifically, but creatine’s well-established ability to support lean mass retention during caloric deficit makes it a logical addition. It’s cheap, safe, and well-studied. No reason not to take 3-5g daily while on a GLP-1.

Emerging drug combinations. Bimagrumab, a drug that blocks the myostatin/activin pathway (essentially a muscle-wasting brake), showed promising results in 2025 clinical trials when combined with semaglutide — helping patients keep muscle while losing weight. This is still experimental, but it signals that the pharmaceutical industry recognizes the muscle problem and is working on solutions.

The Bottom Line on GLP-1s

These drugs are transformative for people with genuine obesity. If your BMI is 35+ and you’ve tried everything else, they can be life-changing. But they are not a free lunch, especially for men over 40 who already face muscle loss as a biological reality.

If you’re going to use them, pair them with resistance training and high protein intake from day one. Don’t wait until you’ve already lost significant muscle to start lifting. The muscle you preserve during weight loss is much easier to keep than the muscle you’d have to rebuild from scratch.

Part 2: The Broader Peptide Landscape — What’s Real and What’s Hype

Beyond GLP-1 drugs, there’s a sprawling world of peptides marketed for everything from healing to anti-aging to cognitive enhancement. Some have real science behind them. Most are running years ahead of the evidence. Here’s what I know from both the research and my own experience.

BPC-157: The Healing Peptide Everyone’s Talking About

BPC stands for “Body Protection Compound,” and it’s a synthetic version of a peptide found naturally in human gastric juice. The animal research on BPC-157 is genuinely impressive — accelerated healing of tendons, ligaments, muscle, gut mucosa, skin, and bone across dozens of studies, mostly in rats.

Here’s the problem: as of early 2026, there are only three published human studies on BPC-157, and all of them are pilot-scale with tiny sample sizes — fewer than 30 people total across all published trials. No randomized, placebo-controlled efficacy trial has been completed. A 2025 systematic review screened 544 papers and included 36 studies, only one of which was in humans.

This doesn’t mean BPC-157 doesn’t work in humans. It means we don’t know if it works in humans, at what dose, for what conditions, or with what side effects. The jump from “heals rat tendons” to “heals your torn rotator cuff” is not a small one.

There are also real safety questions. BPC-157 promotes angiogenesis (new blood vessel formation), which is part of how it accelerates healing. But angiogenesis is also how tumors build their blood supply. Whether BPC-157 could support tumor growth in someone with an undiagnosed cancer is a theoretical concern that hasn’t been addressed by human research because the human research barely exists.

BPC-157 is not FDA-approved for any indication.

TB-500 (Thymosin Beta-4)

TB-500 is a synthetic fragment of Thymosin Beta-4, a protein involved in cell migration, tissue repair, and inflammation regulation. Like BPC-157, the animal data is interesting, and like BPC-157, the human clinical evidence is extremely thin.

TB-500 is often stacked with BPC-157 under the theory that they work on different healing pathways and complement each other. That theory makes biological sense, but it hasn’t been validated in human trials.

GHK-Cu: The Copper Peptide

GHK-Cu is a naturally occurring copper-binding tripeptide that declines with age. It’s been studied primarily for skin health — a 2024 randomized controlled trial with 60 women found 31% wrinkle reduction and 28% improved skin elasticity with topical GHK-Cu cream over 12 weeks. Another 2024 study showed 25% faster skin healing after laser resurfacing.

The skin evidence is actually decent for a peptide. The broader anti-aging and tissue healing claims, however, are mostly extrapolated from cell culture and animal studies.

My experience: I tried GHK-Cu and honestly didn’t notice much of anything — no obvious changes in skin, recovery, or anything else I could point to. That doesn’t mean it doesn’t work; it means that whatever effect it had wasn’t noticeable enough to distinguish from doing nothing. For something that costs real money and requires injections, “I couldn’t tell if it was doing anything” is a relevant data point.

The GLOW Stack: BPC-157 + TB-500 + GHK-Cu

I’ve also used the GLOW peptide blend, which combines all three of the peptides above into a single product. The theory is that you get the synergistic healing benefits of all three: BPC-157’s gut and tissue healing, TB-500’s anti-inflammatory and repair properties, and GHK-Cu’s collagen and skin benefits.

In practice, I have to be honest — I can’t point to clear, concrete results from using it. I didn’t have a specific injury I was trying to heal, which may be part of it. If you’ve got a nagging tendon issue or a recovery problem, maybe you’d notice more. But taking it as a general “feel better, recover faster” supplement, I didn’t feel measurably different.

That said, the evidence base for all three of these peptides in humans is thin enough that my personal experience is about as valid as anything else out there. We’re all running a personal experiment here because the clinical trials haven’t caught up yet.

Semax and Selank: The Anxiety Peptides (and My Best Peptide Experience)

Now this is where I have something genuinely positive to share.

Selank is a synthetic peptide based on the naturally occurring immunomodulatory peptide tuftsin. It was developed in Russia and has been studied in over 800 patients across clinical trials — making it, somewhat surprisingly, one of the better-studied peptides out there. Published research shows anxiolytic effects comparable to benzodiazepine drugs, but without the sedation, cognitive impairment, or addiction potential that makes benzos problematic.

Semax is a synthetic analog of ACTH (adrenocorticotropic hormone), also developed in Russia. Its evidence base is more focused on cognitive function and neuroprotection than anxiety specifically, though it has modest data for anxiety reduction as a secondary outcome.

My experience: I take 1 mg each of Semax and Selank before situations that trigger my social anxiety — presentations, new social situations, anything where I’d normally feel that chest-tightening, mind-racing discomfort that makes it hard to be present. And they work. Noticeably. The anxiety doesn’t disappear entirely, but the edge comes off in a way that lets me function normally instead of white-knuckling through it.

I’m not saying this is a replacement for therapy or proper anxiety treatment. But for situational anxiety — the kind where you know exactly when you need help and can plan for it — Semax and Selank have been the most clearly effective peptides I’ve tried, by a wide margin.

The important caveat: Selank’s clinical evidence comes primarily from Russian studies, and Western medical literature hasn’t replicated these trials independently. The studies that exist are real, peer-reviewed, and published — they’re not fabricated. But the bar for scientific confidence is higher than what’s currently available. I’m comfortable using them based on the existing evidence plus my own experience, but I want you to know what you’re working with.

Part 3: The Stuff Nobody Wants to Talk About

Regulation and Sourcing

Most peptides sold online are marketed as “research chemicals — not for human consumption.” This is a legal fiction that everyone involved understands. You’re buying them to inject into yourself, and the company selling them knows that. But the label protects them legally and means the product isn’t subject to FDA manufacturing standards.

What this means practically:

No guarantee of purity. What’s in the vial might not match the label. Contaminants, incorrect concentrations, and degraded product are all real possibilities.
No standardized dosing. Dosing recommendations come from clinical trials (when they exist), online forums, and word of mouth — not from FDA-approved prescribing information.
No adverse event reporting. When someone has a bad reaction, there’s no systematic way for that information to reach other users or researchers.

If you’re going to use peptides, sourcing from reputable suppliers who provide third-party certificates of analysis (CoA) is the minimum bar. Even then, you’re accepting a level of risk that doesn’t exist with FDA-approved medications.

The Cost-Benefit Calculation for Men Over 40

Here’s how I think about the peptide landscape as someone who’s tried several of them:

Worth serious consideration:

GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) for men with genuine obesity — the evidence is overwhelming, the drugs are FDA-approved (or in late-stage trials), and the muscle loss problem is manageable with proper training and nutrition. These are legitimate medical tools prescribed by doctors.
Semax and Selank for situational anxiety — the evidence is reasonable (especially for Selank), my personal experience has been consistently positive, and the risk profile appears low based on available data.

Interesting but evidence-thin:

BPC-157 for injury healing — the biological rationale is strong and the animal data is compelling, but the human evidence is almost nonexistent. If you’re dealing with a stubborn injury and conventional treatment hasn’t worked, some people try this as a Hail Mary. Just know you’re experimenting, not following proven medicine.
GHK-Cu for skin and anti-aging — the topical evidence is actually decent, but the injectable evidence for systemic effects is much weaker. I didn’t notice anything from my personal use.

Not worth the money in my experience:

The GLOW stack (BPC-157 + TB-500 + GHK-Cu) as a general wellness/recovery tool — if you don’t have a specific injury to heal, I couldn’t tell it was doing anything. Save your money for quality food, creatine, and protein.

What I’d Tell a Friend

If someone I knew was asking about peptides, here’s what I’d say:

If you need to lose a significant amount of weight and you’ve tried diet and exercise without success, talk to your doctor about GLP-1 drugs. They’re real medicine with real evidence. Just don’t skip the resistance training and protein — the muscle you lose is hard to get back, and at our age, we can’t afford to give any of it up.

If you’re curious about the broader peptide world, start with understanding that most of it is genuinely experimental. The gap between “this worked in a rat” and “this will work in you” is enormous. Some peptides — Selank being the best example — have crossed that gap at least partially. Most haven’t.

And whatever you do, don’t let Instagram peptide influencers convince you that a stack of six injectable research chemicals is the shortcut to looking and feeling 25 again. The fundamentals — training, protein, sleep, consistency — still do more than anything in a vial. I’ve tried the vials. I know.

FAQ

Are GLP-1 drugs safe long-term? Semaglutide has the longest track record — it’s been prescribed since 2017 for diabetes and since 2021 for weight management. The most common side effects are gastrointestinal (nausea, vomiting, diarrhea), which typically improve over time. Serious but rare risks include pancreatitis and gallbladder problems. Long-term cardiovascular data has actually been positive — the SELECT trial showed semaglutide reduced major cardiovascular events by 20% in adults with obesity. But we’re still in the early years of widespread use, and the 10-20 year safety picture isn’t fully known yet.

Can I take peptides with my prescription medications? This is the kind of question your doctor needs to answer, not a fitness blog. Drug interactions with research peptides are poorly characterized because the human studies barely exist. If you’re on blood thinners, immunosuppressants, or cancer medications, the angiogenesis-promoting effects of BPC-157 are a particular concern worth discussing.

Do I need to inject peptides, or can I take them orally? It depends on the peptide. GLP-1 drugs come in both injectable and oral forms (oral semaglutide exists as Rybelsus). Most research peptides (BPC-157, GHK-Cu, Semax, Selank) are typically administered as subcutaneous injections or nasal sprays. Oral peptides generally have poor bioavailability because stomach acid breaks them down. BPC-157 is an exception that may retain some activity orally since it’s derived from gastric juice, but the clinical evidence for oral dosing is even thinner than for injections.

Is it legal to buy peptides online? In the US, buying peptides marketed as “research chemicals” occupies a legal gray area. It’s not illegal to purchase them, but it’s not the same as buying a prescription medication. GLP-1 drugs (semaglutide, tirzepatide) are prescription-only and should only be obtained through a licensed healthcare provider. The FDA has cracked down on compounding pharmacies selling knockoff semaglutide, so be cautious about sources claiming to sell “compounded” GLP-1 medications.

If I’m on a GLP-1, how much protein do I need? The evidence-based range during GLP-1 therapy is 1.2 to 2g per kg of body weight daily. For a 200 lb (91 kg) man, that’s 109 to 182g of protein per day. The challenge is hitting these numbers when your appetite is suppressed. Prioritize protein at every meal, use protein shakes as supplements, and front-load protein earlier in the day when appetite tends to be slightly better.

What about growth hormone peptides like Ipamorelin and CJC-1295? I didn’t include these because I haven’t used them and they deserve their own deep dive. These peptides stimulate your body’s natural growth hormone production rather than providing synthetic GH directly. The evidence is mixed — some clinical data exists, particularly for tesamorelin (which is actually FDA-approved for HIV-related lipodystrophy), but the broader category of growth hormone secretagogues is still largely in the experimental stage for anti-aging and muscle-building applications.

Sources

Jastreboff, A. M., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — A Phase 2 trial. New England Journal of Medicine, 389(6), 514-526.
Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 384, 989-1002.
Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387, 205-216.
Lincoff, A. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine, 389, 2221-2232.
SEMALEAN Study. (2025). Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity. PMC/NIH. PMC12673431.
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping. (2026). medRxiv preprint.
Zverev, D., et al. (2016). Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. ResearchGate.
BPC-157 systematic review. (2025). HSS Journal. 544 papers screened, 36 studies included, 1 human study.
GHK-Cu randomized controlled trial. (2024). 60 women, 12 weeks, 0.1% GHK-Cu cream. 31% wrinkle reduction, 28% improved skin elasticity vs. placebo.
GHK-Cu fractional laser study. (2024). Multicenter study, 0.05% GHK-Cu gel. 25% faster epithelial recovery within 72 hours.
Fragala, M. S., et al. (2019). Resistance training for older adults: Position statement from the National Strength and Conditioning Association. Journal of Strength and Conditioning Research, 33(8), 2019-2052.
Eli Lilly. (2025). Retatrutide Phase 3 TRIUMPH trial results. Weight loss up to average of 71.2 lbs.